Product Highlight - KANJINTI

31 Aug 2023
Product Highlight - KANJINTI
Trastuzumab (KANJINTI®)
  • offers identical dosing schedules to trastuzumab RP for metastatic breast cancer, early breast cancer and metastatic gastric cancer1,2
  •  is the first and only trastuzumab biosimilar with single-switch data3
  •  has proven efficacy and safety similar to trastuzumab RP3
  •  NCCN guidelines for Breast Cancer recommend an FDA-approved biosimilar as an appropriate substitution for trastuzumab4
  •  #1 prescribed Trastuzumab Biosimilar in the US5
References:
1. Trastuzumab (KANJINTI) Philippines Prescribing Information. Nov 2019.
2.
Herceptin (trastuzumab) Full Prescribing Info. Available at: https://www.mims.com/hongkong/drug/info/herceptin?type=full. Accessed May 5, 2021.
3.
von Minckwitz G, Colleoni M, Kolberg HC, et al. Lancet Oncol. 2018;19(7):987-998.
4.
National Comprehensive Cancer Network® (NCCN®) / NCCN Foundation®. NCCN Guidelines for Patients®: Metastatic Breast Cancer, 2020. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419. Accessed May 5, 2021.
5.
Data on file, Amgen [#1 Trastuzumab Biosimilar]; Dec 2022. [https://www.kanjinti.com/]


PH-PM-AMGEN-Kanjinti-ONA-HCP-000001-01-2023

Zuellig Pharma Corporation

8th Flr The Curve Bldg, 32nd Cor 3rd Ave,
Bonifacio Global City,
Taguig City 1634
Tel: (+63-2) 8405 5121

Related MIMS Drugs